Source:http://linkedlifedata.com/resource/pubmed/id/19167684
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2009-1-26
|
| pubmed:abstractText |
In newly diagnosed aggressive non-Hodgkin lymphoma (NHL), a positive midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography (PET) scan often carries a poor prognosis, with reported 2-year event-free survival (EFS) rates of 0% to 30% after standard therapy. To determine the outcome of early treatment intensification for midtreatment PET-positive disease, a phase II trial of risk-adapted therapy was conducted. Fifty-nine newly diagnosed patients, 98% with B cell lymphoma, had PET/CT performed after 2 or 3 cycles of first-line chemotherapy. Those with negative PET on semiquantitative visual interpretation completed standard therapy. Those with positive PET received platinum-based salvage chemotherapy, high-dose therapy, and autologous stem cell transplantation (ASCT). Midtreatment PET was positive in 33 (56%); 28 received ASCT with an actuarial 2-year EFS of 75% (95% confidence interval, 60%-93%). On intention-to-treat analysis, 2-year EFS was 67% (53%-86%) in all PET-positive patients and 89% (77%-100%) in PET-negative patients. No association was found between the International Prognostic Index category and the midtreatment PET result. The favorable outcome achieved here in historically poor-risk patients warrants further, more definitive investigation of treatment modification based on early PET scanning.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1523-6536
|
| pubmed:author |
pubmed-author:AmbinderRichard FRF,
pubmed-author:BlackfordAmanda LAL,
pubmed-author:Bolaños-MeadeJavierJ,
pubmed-author:BorowitzMichael JMJ,
pubmed-author:FidykCaroline ACA,
pubmed-author:GoodmanSteven NSN,
pubmed-author:JonesRichard JRJ,
pubmed-author:KasamonYvette LYL,
pubmed-author:RogersKathryn MKM,
pubmed-author:SwinnenLode JLJ,
pubmed-author:WahlRichard LRL,
pubmed-author:ZiessmanHarvey AHA
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
15
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
242-8
|
| pubmed:meshHeading |
pubmed-meshheading:19167684-Adult,
pubmed-meshheading:19167684-Aged,
pubmed-meshheading:19167684-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19167684-Female,
pubmed-meshheading:19167684-Fluorodeoxyglucose F18,
pubmed-meshheading:19167684-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:19167684-Humans,
pubmed-meshheading:19167684-Lymphoma, B-Cell,
pubmed-meshheading:19167684-Lymphoma, Non-Hodgkin,
pubmed-meshheading:19167684-Male,
pubmed-meshheading:19167684-Middle Aged,
pubmed-meshheading:19167684-Platinum Compounds,
pubmed-meshheading:19167684-Positron-Emission Tomography,
pubmed-meshheading:19167684-Prognosis,
pubmed-meshheading:19167684-Risk Assessment,
pubmed-meshheading:19167684-Salvage Therapy,
pubmed-meshheading:19167684-Survival Analysis,
pubmed-meshheading:19167684-Transplantation, Autologous,
pubmed-meshheading:19167684-Treatment Outcome,
pubmed-meshheading:19167684-Young Adult
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.
|
| pubmed:affiliation |
Johns Hopkins University, Baltimore, Maryland, USA. ykasamo1@jhmi.edu
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|